FDA Tightens Scrutiny of Ozempic and Wegovy Marketing, Signaling a Shift in Drug Advertising The Food and Drug Administration (FDA) is increasing its oversight of how Novo Nordisk markets its blockbuster drugs Ozempic and Wegovy, issuing recent warnings about potentially misleading advertising. This comes as the agency faces growing pressure to regulate the booming market … Read more
Novo Nordisk’s Price Cuts: A Turning Point for GLP-1 Medications? Novo Nordisk’s announcement of significant price reductions for its blockbuster GLP-1 medications – Ozempic, Rybelsus and Wegovy – has sent ripples through the healthcare industry. The move, slated to take effect January 1, 2027, will lower the list price of each drug to $675 per … Read more
The Shifting Sands of the GLP-1 Market: Why Eli Lilly is Surging Ahead For years, Novo Nordisk’s Ozempic and Wegovy dominated conversations around GLP-1 drugs – a class of medications initially designed for type 2 diabetes, but quickly gaining traction for weight loss. However, the landscape is changing. While Novo Nordisk was the first to … Read more
Wegovy’s Higher Dose Approved in EU: A Game Changer for Obesity Treatment? The European Commission has granted approval for a higher dose of Novo Nordisk’s Wegovy (semaglutide), offering a potentially more effective option for adults struggling with obesity. This decision, finalized on February 17, 2026, extends the availability of the 7.2mg weekly injection to all … Read more
Novo Nordisk’s Next Act: Can CagriSema Reclaim GLP-1 Dominance? Ozempic has been a major growth driver for Novo Nordisk (NYSE: NVO) for years, becoming a household name in the process. However, the Danish drugmaker has recently lost ground to Eli Lilly (NYSE: LLY) in the competitive GLP-1 market. Can Novo Nordisk regain its footing? The … Read more
The Future of Hypertension Treatment: Could Injections Replace Pills? For decades, managing high blood pressure has meant a lifetime of daily medication. But a significant shift is on the horizon. Fresh long-acting injectable therapies are in late-stage clinical trials, offering the potential to control blood pressure with just two injections per year. This could revolutionize … Read more
The Shifting Sands of the Weight-Loss Market: Opportunities Beyond the GLP-1 Hype Even as Eli Lilly (NYSE: LLY) currently dominates investor attention with its blockbuster GLP-1 drugs, Mounjaro and Zepbound, a closer look reveals potential opportunities in the stocks of its competitors, Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE). The market isn’t a one-horse … Read more
The Rise of Compounded Wegovy: A Glimpse into the Future of Weight Loss & Pharma The recent move by Hims & Hers to offer a compounded version of Wegovy, Novo Nordisk’s blockbuster weight loss drug, isn’t just a business decision – it’s a potential earthquake in the pharmaceutical landscape. Novo Nordisk’s swift accusation of “illegal … Read more
The $49 Wegovy Pill: A Crack in Big Pharma’s Pricing Fortress? The pharmaceutical landscape shifted dramatically this week as telehealth company Hims and Hers Health launched a compounded version of Novo Nordisk’s Wegovy weight-loss pill for just $49 a month. This aggressive pricing, significantly undercutting Novo Nordisk’s $149 list price and anticipated competition from Eli … Read more
Novo Nordisk’s CagriSema: A New Era in Weight Loss and Diabetes Treatment? Novo Nordisk’s recent Phase 3 data for CagriSema is sending ripples through the pharmaceutical industry. The combination drug, pairing semaglutide with the novel amylin receptor agonist cagrilintide, demonstrably outperformed Wegovy in clinical trials, offering a potentially significant leap forward in the treatment of … Read more